Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002;52(4):273-85.
doi: 10.1055/s-0031-1299891.

Synthesis, biological activity and molecular modeling studies of 1,2,3,4-tetrahydroisoquinoline derivatives as conformationally constrained analogues of KN62, a potent antagonist of the P2X7-receptor containing a tyrosine moiety

Affiliations

Synthesis, biological activity and molecular modeling studies of 1,2,3,4-tetrahydroisoquinoline derivatives as conformationally constrained analogues of KN62, a potent antagonist of the P2X7-receptor containing a tyrosine moiety

Pier Giovanni Baraldi et al. Arzneimittelforschung. 2002.

Abstract

A new series of ring constrained analogues of the P2X7 receptor antagonist KN62 (1-[N,O-bis(1,5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4- phenylpiperazine, CAS 127191-97-3) containing the 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid core with S configuration in position 3 was synthesised and their antagonist activities were tested on human macrophage cells. While KN62 is a potent antagonist of the P2X7 receptor, these novel compounds are weak antagonists of the purinergic P2X7 receptor and only one compound (5) showed appreciable activity as P2X7 antagonist, which was 30 times weaker than that reported for KN62. Along with compound 5, the derivatives 11 and 25 were the most active inhibitors in this synthesised series. A molecular modeling study confirmed that an extended rather than folded conformation seems to be crucial for the antagonistic activity at the P2X7 receptor.

PubMed Disclaimer

Similar articles

Cited by

  • P2X(7) receptor: Death or life?
    Adinolfi E, Pizzirani C, Idzko M, Panther E, Norgauer J, Di Virgilio F, Ferrari D. Adinolfi E, et al. Purinergic Signal. 2005 Sep;1(3):219-27. doi: 10.1007/s11302-005-6322-x. Epub 2005 Jul 29. Purinergic Signal. 2005. PMID: 18404507 Free PMC article.
  • Ni-catalysed reductive arylalkylation of unactivated alkenes.
    Jin Y, Wang C. Jin Y, et al. Chem Sci. 2018 Dec 4;10(6):1780-1785. doi: 10.1039/c8sc04279a. eCollection 2019 Feb 14. Chem Sci. 2018. PMID: 30842845 Free PMC article.
  • P2X7 receptor-Pannexin1 complex: pharmacology and signaling.
    Iglesias R, Locovei S, Roque A, Alberto AP, Dahl G, Spray DC, Scemes E. Iglesias R, et al. Am J Physiol Cell Physiol. 2008 Sep;295(3):C752-60. doi: 10.1152/ajpcell.00228.2008. Epub 2008 Jul 2. Am J Physiol Cell Physiol. 2008. PMID: 18596211 Free PMC article.

Publication types

MeSH terms

LinkOut - more resources